药物使用与帕金森病患者8年死亡风险的关联:全药物试验模拟
这项挪威全国观察性队列研究(2004-2020)采用模拟目标试验设计,对14,289例帕金森病患者进行高通量药物筛选,评估219种处方药启动对8年死亡风险的影响。研究发现23种药物与降低死亡风险相关,包括雷尼替丁、质子泵抑制剂、氯沙坦、阿托伐他汀等,但结果仅属探索性,尚不足以支持立即临床应用。
要点
- 在14,289例帕金森病患者中,23种药物与8年死亡风险降低相关。
- 涉及药物包括雷尼替丁、质子泵抑制剂、氯沙坦、阿托伐他汀等。
- 结果为探索性,尚不足以支持立即改变临床用药。
核心结论
- 研究识别出23种与帕金森病患者8年死亡风险降低相关的药物,可能具有疾病修饰潜力,但属探索性发现。
研究设计与样本
- 挪威全国观察性队列研究(2004-2020),采用模拟目标试验设计进行高通量药物筛选。
- 纳入14,289例符合处方分类标准的帕金森病患者(诊断时平均年龄72岁,59%为男性)。
主要发现
- 共筛选219种药物,发现23种药物与8年死亡风险降低相关。
- 相关药物包括雷尼替丁、泮托拉唑与埃索美拉唑、氯沙坦、阿托伐他汀、他达拉非等。
- 还涉及左甲状腺素钠、苯氧甲基青霉素、红霉素、阿奇霉素、4种非甾体抗炎药等。
关键数值与推荐
- 纳入标准:符合处方分类标准的帕金森病、诊断时年龄>25岁、过去2年未处方目标药物。
- 仅纳入在挪威任一药房至少被100人配取的药物,共219种。
- 采用逆概率治疗加权调整潜在混杂因素。
临床怎么用
- 研究结果仅属探索性,不足以支持立即临床应用,但值得进一步研究并考虑纳入临床试验。
局限性
- 研究为观察性设计,结果属探索性,不足以证明因果关系或支持立即临床用药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: There are currently no treatments that can halt or slow the progression of Parkinson disease (PD). The aim of this study was to identify new drug repurposing candidates for PD among existing prescription drugs that could be used to modify the disease course. METHODS: This nationwide observational cohort study (2004-2020) used Norwegian health registries and was conducted as a high-throughput drug screen using an emulated target trial design. All individuals who met our prescription-based classification criteria for PD, were older than 25 years at the time of diagnosis, and were not prescribed the target drug in the past 2 years were included. We emulated a target trial for any drug filled by a minimum of 100 individuals at any pharmacy in Norway, which amounted to a total of 219 drugs. Mortality was used as an outcome to indicate disease progression. We estimated the effect of drug initiation, an observational analog of the intention-to-treat effect, on the 8-year risk of death, comparing initiators of the target drug with initiators of drugs within the same Anatomical Therapeutic Chemical classification system level 1 group. Inverse probability of treatment weighting was used to adjust for potential confounders. RESULTS: The study included 14,289 individuals with PD (mean age 72 at diagnosis, 59% male) and identified 23 drugs associated with reduced mortality risk at 8 years. These drugs included ranitidine (histamine-2 blocker); pantoprazole and esomeprazole (proton pump inhibitors); losartan (angiotensin receptor blocker); atorvastatin (for high cholesterol); tadalafil (for erectile dysfunction); levothyroxine sodium (thyroid hormone); phenoxymethylpenicillin, erythromycin, and azithromycin (antibiotics); 4 nonsteroidal anti-inflammatory drugs; combined codeine/paracetamol and tramadol (opioid analgesics); zopiclone and melatonin (sleep aids); mianserin (antidepressant); mometasone (nasal corticosteroid); 2 opium-derived cough medicines; and dexamethasone (ophthalmologic corticosteroid). DISCUSSION: Our study identified several drugs with potential disease-modifying properties that could be candidates for future clinical trials. It highlights the potential of repurposing existing medications to advance drug development. While these findings are exploratory and, therefore, insufficient to justify immediate clinical application, they warrant further investigation and potential inclusion in clinical trials.
引用
- Tuominen JA, Riise T, Romanowska J, et al. Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease: Drug-Wide Trial Emulation. Neurology. 2025. PMID: 40644656. doi:10.1212/WNL.0000000000213783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。